120302-61-6

Basic information

• Product Name: Phosphonium, [2-(4-fluorophenyl)-2-oxoethyl]triphenyl-, bromide
• CAS NO: 120302-61-6
• Molecular Formula: C26H21FOP.Br
• Molecular Weight: 479.328
• Mol File: 120302-61-6.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: Phosphonium, [2-(4-fluorophenyl)-2-oxoethyl]triphenyl-, bromide(CAS DataBase Reference)
• NIST Chemistry Reference: Phosphonium, [2-(4-fluorophenyl)-2-oxoethyl]triphenyl-, bromide(120302-61-6)
• EPA Substance Registry System: Phosphonium, [2-(4-fluorophenyl)-2-oxoethyl]triphenyl-, bromide(120302-61-6)

Safety Data

• Hazardous Substances Data: 120302-61-6(Hazardous Substances Data)

Upstream product

• 403-42-9 1-(4-fluorophenyl)ethanone 
• 603-35-0 triphenylphosphine 
• 403-29-2 2-bromo-4'-fluoroacetophenone 

Downstream Products

• 63072-14-0 1-(4-fluorophenyl)-2-(triphenyl-λ⁵phosphanylidene)ethanone 
• 1256284-90-8 1-(4-fluorophenyl)-2-(9-methyl-2,3,4,9-tetrahydro-1H-carbazol-4-yl)ethanone 
• 51594-59-3 1-(4-fluorophenyl)-2-propen-1-one 
• 1422452-55-8 (E)-5-(cyclohexylmethoxy)-3-(3-(4-fluorophenyl)-3-oxoprop-1-enyl)-4H-chromen-4-one 
• 1422452-67-2 (E)-5-(cyclohexylmethoxy)-3-(3-(4-fluorophenyl)-3-hydroxyprop-1-enyl)-4H-chromen-4-one 
• 92-52-4 biphenyl 

Relevant articles and documents

Functionality study of chalcone-hydroxypyridinone hybrids as tyrosinase inhibitors and influence on anti-tyrosinase activity

In an attempt to synthesise new tyrosinase inhibitors, we designed and synthesised a series of chalcone-hydroxypyridinone hybrids as potential tyrosinase inhibitors adopting strategic modifications of kojic acid. All the newly synthesised compounds were characterised by NMR and mass spectrometry. Initial screening of the target compounds demonstrated that compounds 1a, 1d, and 1n had relatively strong inhibitory activities against tyrosinase monophenolase, with IC50 values of 3.07 ± 0.85, 2.25 ± 0.8 and 2.75 ± 1.19 μM, respectively. The inhibitory activity against monophenolase was 6- to 8-fold higher than that of kojic acid. Compounds 1a, 1d, and 1n also showed inhibition of diphenolase, with IC50 values of 17.05 ± 0.07, 11.70 ± 0.03 and 19.3 ± 0.28 μM, respectively. The inhibition kinetics of diphenolase indicates that compounds 1a and 1d induce reversible inhibition on tyrosinase. Finally, we found that copper coordination should be one of the important inhibitory mechanism of these compounds in tyrosinase.

PYRROLIDINE DERIVATIVES AS PPAR AGONISTS

The present invention discloses a class of pyrrolidine derivatives as PPAR agonist, and their use for the treatment of some diseases of PPAR receptor-associated pathways (such as nonalcoholic steatohepatitis and concurrent fibrosis, insulin resistance, primary biliary cholgangitis, dyslipidenmia, hyperlipidemia, hypercholesterolemia, atherosclerosis, hypertriglyceridemia, cardiovascular disease, obesity or the like). In particular, the present invention discloses a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.

Catalytic Cyclooligomerization of Enones with Three Methylene Equivalents

Cyclic structures are highly represented in organic molecules, motivating a wealth of catalytic methods targeting their synthesis. Among the various ring-forming processes, cyclooligomerization reactions possess several attractive features but require addressing a unique challenge associated with controlling ring-size selectivity. Here we describe the catalytic reductive cocyclooligomerization of an enone and three carbene equivalents to generate a cyclopentane, a process that constitutes a formal [2 + 1 + 1 + 1]-cycloaddition. The reaction is promoted by a (quinox)Ni catalyst and uses CH2Cl2/Zn as the C1 component. Mechanistic studies are consistent with a metallacycle-based pathway, featuring sequential migratory insertions of multiple carbene equivalents to yield cycloalkanes larger than cyclopropanes.